Fractyl Health (NASDAQ:GUTS) Director William Bradley Buys 68,493 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director William Bradley bought 68,493 shares of Fractyl Health stock in a transaction dated Wednesday, June 10th. The shares were acquired at an average price of $0.73 per share, with a total value of $49,999.89. Following the completion of the purchase, the director directly owned 84,622 shares in the company, valued at $61,774.06. This trade represents a 424.66% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Fractyl Health Stock Performance

NASDAQ:GUTS opened at $0.72 on Friday. The stock has a market cap of $114.85 million, a P/E ratio of -0.56 and a beta of 2.34. The stock has a 50 day simple moving average of $0.69 and a 200 day simple moving average of $1.07. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 1.41. Fractyl Health, Inc. has a 1-year low of $0.38 and a 1-year high of $2.45.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.23. Research analysts anticipate that Fractyl Health, Inc. will post -0.6 earnings per share for the current year.

Institutional Investors Weigh In On Fractyl Health

A number of institutional investors have recently made changes to their positions in GUTS. Woodline Partners LP grew its position in shares of Fractyl Health by 47.2% in the 1st quarter. Woodline Partners LP now owns 516,921 shares of the company’s stock valued at $615,000 after buying an additional 165,786 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Fractyl Health in the 2nd quarter valued at about $129,000. General Catalyst Group Management LLC bought a new stake in shares of Fractyl Health in the 2nd quarter valued at about $7,912,000. Jane Street Group LLC bought a new stake in shares of Fractyl Health in the 2nd quarter valued at about $31,000. Finally, Osaic Holdings Inc. grew its position in shares of Fractyl Health by 460.3% in the 2nd quarter. Osaic Holdings Inc. now owns 59,645 shares of the company’s stock valued at $97,000 after buying an additional 49,000 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Canaccord Genuity Group reissued a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a report on Thursday, March 26th. Wall Street Zen raised Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research note on Thursday, June 4th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $5.40.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.